Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224808 | 0.84 | GRM2 (0.42) | GRM2MAP3K5AGXTNOTUMMGLL | |
| SCHEMBL10309786 | 0.77 | AGXT (0.40) | GRM2NR1H2NR1H3AGXTNOTUM | |
| SCHEMBL10175527 | 0.75 | ATM (0.43) | GRM2AGXTMGLLALOX5 | |
| SCHEMBL10174869 | 0.72 | MKNK1 (0.36) | MAP3K5NOTUM | |
| SCHEMBL28289823 | 0.70 | PDK1 (0.48) | MAPTMAP3K5NOTUMLMNA | |
| SCHEMBL11197056 | 0.69 | HTR1A (0.54) | MAPTNOTUMLMNA | |
| SCHEMBL4507051 | 0.68 | AGXT (0.65) | KDM4EMAPTL3MBTL1AGXTMGLL | |
| SCHEMBL25617353 | 0.68 | NOTUM (0.69) | NOTUM | |
| SCHEMBL23844438 | 0.68 | L3MBTL3 (0.46) | L3MBTL1AGXTNOTUMMGLLALOX5 | |
| SCHEMBL3265073 | 0.67 | AR (0.45) | L3MBTL1NOTUMMGLLALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | GRM2 726/4885KDM4E 2025/4885POLB 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.